Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Appointed director
|
|
RELMADA THERAPEUTICS, INC. (RLMD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 2% stake in RELMADA THERAPEUTICS INC |
| 05/30/2023 |
4
| TRAVERSA SERGIO (CEO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 527,211 options to buy
@ $3.37, valued at
$1.8M
|
|
| 05/30/2023 |
4
| Shenouda Maged (CFO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 317,643 options to buy
@ $3.37, valued at
$1.1M
|
|
| 05/30/2023 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
| 05/30/2023 |
4
| Kelly Paul Edward (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
| 05/30/2023 |
4
| GLASSPOOL JOHN (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
| 05/30/2023 |
4
| Fedeli Fabiana (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 200,000 options to buy
@ $4.22, valued at
$844k
|
|
| 05/30/2023 |
4
| Ence Chuck (CA and CO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 321,238 options to buy
@ $3.37, valued at
$1.1M
|
|
| 05/30/2023 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
| 05/25/2023 |
8-K
| Appointed a new director |
| 05/24/2023 |
4
| O'Gorman Cedric (Chief Medical Officer) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Bought 10,000 shares
@ $3.18, valued at
$31.8k
|
|
| 05/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets As of As of March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 28,894,360 $ 5,395,905 Short-term investments 103,547,634 142,926,781 Other receivables - 512,432 Prepaid expenses 3,089,580 4,035,186 Total current assets 135,531,574 152,870,304 Other assets 34,875 34,875 Total assets $ 135,566,449 $ 152,905,179 Commitments and Contingencies Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 4,421,965 $ 5,261,936 Accrued expenses 5,675,292 7,206,941 Total current liabilities 10,097,257 12,468,877 Total liabilities 10,097,257 12,468,877 Stockholders’ Equity: Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding - -..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/19/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results CORAL GABLES, Fla., Mar 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022. The Company will host a conference call today, Thursday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time. “Following the availability of top-line results in the Reliance I , one of two Phase 3 sister two-arm, placebo-controlled, pivotal studies evaluating REL-1017 25mg as a potential adjunctive treatment for major depressive disorder , in December 2022, we have..." |
|
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Relmada Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Relmada Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5% stake in Relmada Therapeutics Inc. |
| 02/06/2023 |
5/A
| TRAVERSA SERGIO (CEO) has filed a Form 5/A on RELMADA THERAPEUTICS, INC. |
| 02/02/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
|
|
|